Molecular Formula | C20H19ClFN5OS |
Molar Mass | 431.91 |
Density | 1.430±0.06 g/cm3(Predicted) |
Melting Point | 177-179°C |
Boling Point | 605.5±65.0 °C(Predicted) |
Solubility | DMSO: ≥ 34 mg/mL |
Appearance | Solid |
Color | Off-White |
pKa | 5.20±0.10(Predicted) |
Storage Condition | Refrigerator |
Use | The MK-8745 is an aurora kinase inhibitor (aurora A) with an IC50 value of 0.6 nM. |
Target | Aurora A Aurora B |
In vitro study | In non-Hodgkin's lymphoma (NHL) cell lines, MK-8745 leads to cell cycle arrest at the G2/ M phase with aggregation of tetraploid nuclei followed by cell death. MK-8745 induced p21(WAF1/CIP1) and CYCB1, indicating cell cycle arrest and increased G2/M phase cell population. MK-8745 treatment resulted in rapid degradation of Aurora-A substrates (TACC3, Eg5, and TPX2) followed by a decrease in phosphorylation Aurora-A. When in vitro in a variety of cell lines, MK8745 induces apoptotic cell death in a p53-dependent manner. In p53 wild-type cells, MK8745 induces p53 phosphorylation (ser15) and increases the expression of p53 protein. P53-dependent apoptosis of MK8745 transfected with wild-type p53 in HCT 116 p53(-/-) cells was further confirmed. |
Reference Show more | 1. Chowdhury, A., S. Chowdhury, M.Y., et al. Tsai, A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma, 2012. 53(3): p. 462-712. Shionome, Y., et al. Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors. PLoS One, 2013. 8(1): p. e55457. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.315 ml | 11.576 ml | 23.153 ml |
5 mM | 0.463 ml | 2.315 ml | 4.631 ml |
10 mM | 0.232 ml | 1.158 ml | 2.315 ml |
5 mM | 0.046 ml | 0.232 ml | 0.463 ml |